伊奥尼斯制药 IONS 深 沪
已收盘 05-08 16:00:00 美东时间
75.71
-0.310
-0.41%
华盛通- 最 高77.40
- 今 开76.45
- 成交量 165.62万股
- 最 低 75.24
- 昨 收 76.02
- 总市值 125.12亿
- 52周最高 86.74
- 市盈率 静 --
- 换手率 1.00%
- 52周最低 32.00
- 委 比 -91.30%
- 总股本 1.65亿
- 历史最高 86.74
- 量 比 1.03
- 振 幅 2.84%
- 历史最低 6.25
- 每 手 1
- 风险率 17.68%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 潜在涨幅128.69%！Immunic获HC Wainwright & Co.升目标价至22美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Immunic"买入"评级，目标价从5美元升至22美元；花旗：维持ServiceNow"买入"评级，目标价从154美元升至158美元
05-01 10:49
U.S. RESEARCH ROUNDUP-Alphabet, Amazon, Meta
U.S. RESEARCH ROUNDUP-Alphabet, Amazon, Meta April 30 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Alphabet, Amazon and Meta on Thursday. HIGHLIGHTS * Alphabet Inc GOOG.O : Oppenheimer raises target price to $425 from
04-30 15:23
Ionis Pharmaceuticals’ Earnings Call Flags Growth and Risks
Ionis Pharmaceuticals Inc. (($IONS)) has held its Q1 earnings call. Read on for...
04-30 08:45
财报速睇 | 伊奥尼斯制药 2026财年Q1营收2.46亿美元，同比增长87.0%；归母净利润亏损0.93亿美元，同比亏损缩窄37.0%
华盛资讯4月30日讯，伊奥尼斯制药公布2026财年Q1业绩，公司Q1营收2.46亿美元，同比增长87.0%，归母净利润亏损0.93亿美元，同比亏损缩窄37.0%。
04-30 02:47
Ionis Pharmaceuticals shares are trading higher after the company reported better-than-expected Q1 financial results and raised its FY26 sales guidance above estimates.
Ionis Pharmaceuticals shares are trading higher after the company reported bett...
04-29 20:57
财报速睇 | 伊奥尼斯制药2026财年Q1营收2.46亿美元，同比增长86.4%；归母净利润亏损0.93亿美元，同比亏损缩窄36.7%
华盛资讯4月29日讯，伊奥尼斯制药公布2026财年Q1业绩，公司Q1营收2.46亿美元，同比增长86.4%，归母净利润亏损0.93亿美元，同比亏损缩窄36.7%。
04-29 20:15
财报速睇 | 伊奥尼斯制药 2026财年Q1营收2.46亿美元，同比增长86.4%；归母净利润亏损0.93亿美元，同比亏损缩窄36.7%
华盛资讯4月29日讯，伊奥尼斯制药公布2026财年Q1业绩，公司Q1营收2.46亿美元，同比增长86.4%，归母净利润亏损0.93亿美元，同比亏损缩窄36.7%。
04-29 20:09
Earnings Scheduled For April 29, 2026
Companies Reporting Before The Bell • Extreme Networks (NASDAQ:EXTR) is likely ...
04-29 19:11
Ionis Pharmaceuticals Raises FY2026 Sales Guidance from $800.000M-$825.000M to $875.000M-$900.000M vs $815.735M Est
Ionis Pharmaceuticals (NASDAQ:IONS) raises FY2026 sales outlook from $800.000 million-$825.000 million to $875.000 million-$900.000 million vs $815.735 million estimate.
04-29 19:04
Ionis Pharmaceuticals Q1 Adj. EPS $(0.30) Beats $(0.91) Estimate, Sales $246.000M Beat $195.628M Estimate
Ionis Pharmaceuticals (NASDAQ:IONS) reported quarterly losses of $(0.30) per share which beat the analyst consensus estimate of $(0.91) by 67.03 percent. This is a 67.74 percent increase over losses of $(0.93) per share
04-29 19:03
